about
Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulationDapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-enDose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation.Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil.Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects.Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles.Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats.Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.Dapoxetine and paroxetine for the treatment of premature ejaculation.Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats.Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits.Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.Application of neural networks to pharmacodynamics.Pharmacodynamic system analysis of the biophase level predictor and the transduction function.An algorithm for constrained deconvolution based on reparameterization.Optimal extravascular dosing intervals.Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers.A System Approach to Pharmacodynamics. Plasma Iron Mobilization by Endogenous Erythropoietin in the Sheep Fetus; Evidence of Threshold Response in Spontaneous HypoxemiaOrally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidinesPhenobarbital removal characteristics of three brands of activated charcoals: a system analysis approachApplication of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy malesEngineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteinsPharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparinPharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimensApplication of in vitro-in vivo correlations (IVIVC) in setting formulation release specificationsPharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndromeDapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteersPharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal
P50
Q28376544-1BE329B4-AA07-4D91-831F-59FF0830A467Q34562839-6BEE92BD-206A-42C5-BEB9-7A5FFC58AF62Q35009428-1864DC0D-A970-4271-BC8D-0E1C4B11B0BDQ36467274-659913C6-0051-411C-A7CF-A4975B044DD2Q37054013-7C3BD3AC-7547-420C-B856-1C1832F31C26Q37233228-CFDE45F6-EDC1-45E0-A83F-B3ACA145FB60Q37275476-C13986AB-7B7A-4BE3-99D4-D69F6AAAC9CAQ37343974-1A785B7C-6A56-4725-9350-66F94922A577Q39102210-A00392B3-F6DA-4FAF-A427-2882F5CC929DQ39150129-FD3DC8C2-CF07-4A65-AA22-A81F64144EE7Q41087388-DE2385BC-AAC3-4AD4-BBA2-E7B15E4C965BQ43916480-4278A51E-84AD-4753-90F8-33D7739065A9Q46038779-35254D06-A503-4121-A771-BB7DFCBEA576Q46070670-698D839E-202B-484A-933C-B55F32C49044Q46228939-897BCE39-08F7-4379-A762-CA24B987DF3DQ46419553-E635DF45-C7EA-4B81-8924-5D702ADB56FDQ46450766-95E3B65D-5568-4BE5-9689-A4F9DDEEE816Q46607001-2E036DED-EE18-4C49-B5C9-8BBF056519E7Q46971903-186C7BAC-EC3C-48DC-95E9-0C12E11240D6Q48449294-EC047664-A320-4A8A-8873-C254AFDD4670Q50251124-F7008EAB-8364-4312-87F4-2B2CDCF87DF5Q51638535-BC00F243-2BDC-4B06-944A-3583D8011FADQ51644780-FB2D06B9-405B-44FA-962F-9DEC363582A3Q51657438-419F760C-B098-470C-AEB6-E33B7C7B9108Q51684029-FB76FE78-43ED-4D1C-B8DC-3F5C93B397B5Q52426591-387AB510-2FD4-4C27-83AF-622F92E7C701Q52444789-E47ACF7E-F008-4CC9-987B-D3A41180A61EQ53912240-D6A4342A-9A7A-4922-8313-8B44C64914E2Q55059545-D531163A-763F-4EB7-B331-1A2960274B12Q61636089-188B4736-83C9-4E6D-A17E-38FC5DC0055DQ71403148-241FE611-21E5-4CDB-BC59-00314DF82CE1Q72380199-AE09F0D9-86A1-4F82-9A13-18D3F3C18A6EQ72901884-6AB6B71F-E738-4FD5-BD44-321F5FDA0831Q73143449-BC701FD1-E639-445F-91F4-148FA8744FF6Q73779375-A41A2585-79D8-4F01-9FDD-C75645594D62Q74339441-C3E8E64D-D0F2-4506-955D-741BA77D4404Q74405548-5089C1A9-D904-4B6C-9685-0B3EF5CAEBB5Q77956562-CB51CDD5-307D-402B-9400-B1849A012388Q79830141-89BF4248-722A-4B72-BF48-CFB872DAE0C2Q80142358-A8839374-3ECC-4DAA-B155-9FB08B586F07
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nishit B. Modi
@ast
Nishit B. Modi
@en
Nishit B. Modi
@es
Nishit B. Modi
@nl
Nishit B. Modi
@sl
type
label
Nishit B. Modi
@ast
Nishit B. Modi
@en
Nishit B. Modi
@es
Nishit B. Modi
@nl
Nishit B. Modi
@sl
altLabel
Nishit Modi
@en
prefLabel
Nishit B. Modi
@ast
Nishit B. Modi
@en
Nishit B. Modi
@es
Nishit B. Modi
@nl
Nishit B. Modi
@sl
P106
P1153
7005469469
P31
P496
0000-0002-5111-867X